Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy

Urology - Tập 68 - Trang 820-824 - 2006
Cheryn Song1, Jae Y. Ro2, Moo-Song Lee3, Sung-Joon Hong4, Byung-Ha Chung4, Han Yong Choi5, Sang-Eun Lee6, Eunsik Lee6, Choung-Soo Kim1, Hanjong Ahn1
1Department of Urology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
2Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
3Department of Preventive Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
4Yonsei University College of Medicine, Severance Hospital, Seoul, Korea
5Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Korea
6Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea

Tài liệu tham khảo

Whittemore, 1994, Prostate cancer, vol 19, 309 2003 Song, 2005, Nomograms for the prediction of pathologic stage of clinically localized prostate cancer in Korean men, J Korean Med Sci, 20, 262, 10.3346/jkms.2005.20.2.262 Roehl, 2004, Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results, J Urol, 172, 910, 10.1097/01.ju.0000134888.22332.bb D’Amico, 2000, Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer, J Clin Oncol, 18, 1164, 10.1200/JCO.2000.18.6.1164 Pound, 1999, Natural history of progression after PSA elevation following radical prostatectomy, JAMA, 281, 1591, 10.1001/jama.281.17.1591 Hull, 2002, Cancer control with radical prostatectomy alone in 1,000 consecutive patients, J Urol, 167, 528, 10.1016/S0022-5347(01)69079-7 Latini, 2004, Differences in clinical characteristics and disease-free survival for Latino, African-American, and non-Latino white men with prostate cancer: data from CaPSURE, J Urol, 171, 124, 10.1016/S0022-5347(18)37729-2 Lam, 2004, Is Hispanic race an important predictor of treatment failure following radical prostatectomy for prostate cancer?, J Urol, 172, 1856, 10.1097/01.ju.0000141783.67470.55 Egawa, 2001, A study of pretreatment nomograms to predict pathological stage and biochemical recurrence after radical prostatectomy for clinically respectable prostate cancer in Japanese men, Jpn J Clin Oncol, 31, 74, 10.1093/jjco/hye018 Hsu, 2004, E-cadherin expression in prostate adenocarcinoma in Chinese and its pathological correlates, Urol Int, 73, 36, 10.1159/000078802 Egawa, 2001, Treatment outcome by risk group after radical prostatectomy in Japanese men, Int J Urol, 8, 295, 10.1046/j.1442-2042.2001.00301.x Freedland, 2005, The prostatic specific antigen era is alive and well: prostatic specific antigen and biochemical progression following radical prostatectomy, J Urol, 174, 1276, 10.1097/01.ju.0000173907.84852.ec Man, 2003, Asian race and impact on outcomes after radical radiotherapy for localized prostate cancer, J Urol, 170, 901, 10.1097/01.ju.0000081423.37043.b4 Derweesh, 2004, Continuing trends in pathological stage migration in radial prostatectomy specimens, Urol Oncol, 22, 300, 10.1016/j.urolonc.2003.11.011 van Houten, 2000, Differences in reproductive endocrinology between Asian men and Caucasian men—a literature review, Asian J Androl, 2, 13 Wu, 2001, Lifestyle determinants of 5α-reductase metabolites in older African-American, white, and Asian-American men, Cancer Epidemiol Biomarkers Prev, 10, 533 Hoffman, 2000, Is low serum free testosterone a marker for high grade prostate cancer?, J Urol, 163, 824, 10.1016/S0022-5347(05)67812-3 Zhang, 2002, Association between prostate cancer and serum testosterone levels, Prostate, 53, 179, 10.1002/pros.10140 Massengill, 2003, Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy, J Urol, 169, 1670, 10.1097/01.ju.0000062674.43964.d0 Raivio, 2003, Reduced circulating androgen bioactivity in patients with prostate cancer, Prostate, 55, 194, 10.1002/pros.10234